Literature DB >> 33914017

Biosimilar Ranibizumab (SB11) vs Reference Ranibizumab-Diving Deeper for Safety and Efficacy.

Ashish Sharma1, Nilesh Kumar1, Nikulaa Parachuri1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33914017     DOI： 10.1001/jamaophthalmol.2021.1037

Source DB:  PubMed          Journal:  JAMA Ophthalmol        ISSN： 2168-6165            Impact factor:   7.389


× No keyword cloud information.
  1 in total

1.  Ranibizumab Biosimilar (Razumab) vs Innovator Ranibizumab (Lucentis) in neovascular age-related macular degeneration (n-AMD)- efficacy and safety (BIRA study).

Authors:  Ashish Sharma; Nilesh Kumar; Nikulaa Parachuri; Francesco Bandello; Baruch D Kuppermann; Anat Loewenstein
Journal:  Eye (Lond)       Date:  2021-06-22       Impact factor: 4.456
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.